New Key Statistics Module, Z-Score and F-Score
NAS:MACK Key Ratios
Market Cap $ M | 213.91 |
Enterprise Value $ M | 194.45 |
P/E(ttm) | -- |
PE Ratio without NRI | -- |
Forward PE Ratio | -- |
Price/Book | 11.24 |
Price/Sales | -- |
Price/Free Cash Flow | -- |
Price/Owner Earnings | -- |
Payout Ratio % | -- |
Revenue (TTM) $ M | -- |
EPS (TTM) $ | -0.08 |
Beneish M-Score | 0 |
10-y EBITDA Growth Rate % | 40.40 |
5-y EBITDA Growth Rate % | 50.20 |
y-y EBITDA Growth Rate % | -- |
EV-to-EBIT | -89.36 |
EV-to-EBITDA | -89.36 |
PEG | -- |
Shares Outstanding M | 14.53 |
Net Margin (%) | -- |
Operating Margin % | -- |
Pre-tax Margin (%) | -- |
Quick Ratio | 43.50 |
Current Ratio | 43.50 |
ROA % (ttm) | -6.06 |
ROE % (ttm) | -6.22 |
ROIC % (ttm) | -1,038.17 |
Dividend Yield % | -- |
Altman Z-Score | -- |
Piotroski F-Score | 3.00 |
Positive ROA | N |
Positive CFROA | N |
Higher ROA y-y | Y |
Cash flow > Earnings | N |
Lower Leverage y-y | Y |
Higher Current Ratio y-y | Y |
Less Shares Outstanding y-y | N |
Gross Margin Increase y-y | N |
Higher Asset Turnover y-y | N |
MACK Number of Guru Trades
MACK Volume of Guru Trades
Gurus Latest Trades with NAS:MACK
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
NAS:MACK is held by these investors
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Merrimack Pharmaceuticals Inc Insider Transactions
No Available Data
News about NAS:MACK
Total 0- 1